Nasdaq gnlx.

GNLX Genelux Corporation Form 8-K - Current report. 0001231457 false 0001231457 2023-10-10 2023-10-10 iso4217:USD xbrli:shares ... Monitor; Level 2; Movers; Portfolio; Markets; Forums; Menu ...WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...Given GNLX’s positive Phase 2 trial results to-date, my outlook on IPO is a Buy for patient, risk-tolerant life science investors with a long-term hold time frame. ... (NASDAQ:GNLX) was founded ...Web

May 25, 2023 · WESTLAKE VILLAGE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication of positive topline ...

Genelux (NASDAQ: GNLX) is owned by 15.88% institutional shareholders, 5.64% Genelux insiders, and 78.48% retail investors. Aladar Szalay is the largest individual Genelux shareholder, owning 555,000.00 shares representing 2.08% of the company. Aladar Szalay's Genelux shares are currently valued at $6.21M.

Jan 21, 2023 · Companies that could price their IPOs and start trading include Genelux (NASDAQ:GNLX), Elate Group , MorningStar Partners , and Syla Technologies . Intel earnings ... Genelux Corporation (NASDAQ:GNLX) gained 12.9% to $30.82. Franchise Group, Inc. (NASDAQ:FRG) jumped 11.8% to $25.44. Franchise Group revealed the receipt of an unsolicited non-binding proposal to ...GNLX Genelux Corporation Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates4 Wall Street analysts have issued 1 year price objectives for Genelux's shares. Their GNLX share price targets range from $30.00 to $40.00. On average, they predict the company's stock price to reach $35.00 in the next year. This suggests a possible upside of 194.1% from the stock's current price. View analysts price targets for GNLX or view ...Genelux Corp (NASDAQ:GNLX) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% of ...

WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's common stock at a price of $20.00 per share, for gross proceeds of approximately $33 million, before …

About. Genelux Corporation, a Delaware · Highlight. A company researching a leading · Exchange. NASDAQ. Listing Date · NASDAQ. Listing Date. 01/26/2023.

WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have set an average share price target of $34.33. The firm's second quarter results saw it outline $27.1 million cash in hand, which, along with other ...WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 ...WebWESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares of the Company's common stock at a price of $20.00 per share, for gross proceeds of approximately $33 million, before …WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...10% least volatile stocks in US Market. 2.9%. Stable Share Price: GNLX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week. Volatility Over Time: GNLX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...WebNov 17, 2023 · A look at the shareholders of Genelux Corporation (NASDAQ:GNLX) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are retail investors with 57% ownership. Genelux has filed to go public with an IPO on the NASDAQ. 1 year ago - SEC. Get a real-time Genelux Corporation (GNLX) stock price quote with breaking news, …According to the issued ratings of 3 analysts in the last year, the consensus rating for Genelux stock is Buy based on the current 3 buy ratings for GNLX. The average twelve-month price prediction for Genelux is $25.00 with a high price target of $40.00 and a low price target of $10.00. Learn more on GNLX's analyst rating history.Sep 8, 2023 · In the previous quarter, Genelux (NASDAQ:GNLX) missed the analysts' consensus estimate of ($0.12) by $0.09 with a reported earnings per share (EPS) of ($0.21). Learn more on analysts' earnings estimate vs. GNLX's actual earnings. On September 26, an intriguing development occurred in the world of finance. Aladar Szalay, a prominent figure within Genelux (NASDAQ:GNLX), made a significant move by selling off 16,591 shares of the company. The transaction amounted to a staggering $462,000, as revealed in a recently filed Form 4 with the U.S. Securities and …

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...WebGenelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery ...

Jul 20, 2023 · WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ... WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President ...Nov 24, 2023 · Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian ... Webull offers Genelux Corp stock information, including NASDAQ: GNLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNLX stock news, and many more online research tools to help you make informed decisions. So far, 2023 has been a great year for Genelux Corporation (NASDAQ: GNLX), which has seen positive results from trials of its lead therapy Olvi-Vec (olvimulogene nanivacirepvec) that's primarily been active in studies pertaining to ovarian cancer. However, Genelux has also been forthcoming about its V2ACT Immunotherapy, which incorporates …So far, 2023 has been a great year for Genelux Corporation (NASDAQ:GNLX), which has seen positive results from trials of its lead therapy Olvi-Vec (olvimulogene nanivacirepvec) that’s primarily ...Jan 27, 2023 · According to the issued ratings of 3 analysts in the last year, the consensus rating for Genelux stock is Buy based on the current 3 buy ratings for GNLX. The average twelve-month price prediction for Genelux is $25.00 with a high price target of $40.00 and a low price target of $10.00. Learn more on GNLX's analyst rating history. Oct 20, 2023 · Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...

Nasdaq 14,095.21 -8.62(-0.06%) Russell 2000 1,775.06 -26.16(-1.45%) Crude Oil 72.88 -3.78(-4.93%) Gold 1,987.00 +22.70(+1.16%) Genelux Corporation (GNLX) NasdaqCM - NasdaqCM Real Time Price....

In terms of stock performance, immunotherapy developer Genelux (NASDAQ:GNLX) has been the hands-down winner, with shares up an impressive 417% from their IPO price as of Monday's close.

Webull offers Genelux Corp stock information, including NASDAQ: GNLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNLX stock news, and many more online research tools to help you make informed decisions. On September 26, an intriguing development occurred in the world of finance. Aladar Szalay, a prominent figure within Genelux (NASDAQ:GNLX), made a significant move by selling off 16,591 shares of the company. The transaction amounted to a staggering $462,000, as revealed in a recently filed Form 4 with the U.S. Securities and …HC Wainwright started coverage of Genelux ( NASDAQ: GNLX) with a buy rating, stating that it believed the company’s lead oncolytic virus Olvi-Vec is “underappreciated” and could lead to a ...About Pre-Market Quotes. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Bed Bath & Beyond Inc. Common Stock. 1.74%. So far, 2023 has been a great year for Genelux Corporation (NASDAQ: GNLX), which has seen positive results from trials of its lead therapy Olvi-Vec (olvimulogene nanivacirepvec) that's primarily been active in studies pertaining to ovarian cancer. However, Genelux has also been forthcoming about its V2ACT Immunotherapy, which incorporates …WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad ...WebLe titre Ampio Pharmaceuticals (AMEX: AMPE) a chuté vendredi de 45,05% à 3,17 dollars lors de la session ordinaire. L’action Intelligent Bio Solutions (NASDAQ: …The latest price target for . Genelux (NASDAQ: GNLX) was reported by HC Wainwright & Co. on Monday, November 27, 2023.The analyst firm set a price target for …Nov 18, 2023 · Genelux Co. (NASDAQ:GNLX – Free Report) – Brookline Capital Management reduced their FY2023 earnings per share (EPS) estimates for shares of Genelux in a research note issued on Tuesday, November 14th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($1.03) per share for the year, down from their […] In terms of stock performance, immunotherapy developer Genelux (NASDAQ:GNLX) has been the hands-down winner, with shares up an impressive 417% from their IPO price as of Monday's close.WebGenelux (NASDAQ:GNLX) PT Lowered to $30.00 americanbankingnews.com - November 25 at 3:58 AM: Genelux VP Sold $191K In Company Stock benzinga.com - November 23 at 12:58 PM: Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25% finance.yahoo.com - November 17 at 8:49 AM

Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...WebNov 1, 2023 · Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. As of November 1, 2023, the average one-year price target for ... Genelux Co. (NASDAQ:GNLX – Free Report) – Equities researchers at HC Wainwright issued their FY2023 EPS estimates for Genelux in a research report issued on Monday, November 27th.HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($1.17) per share for the year. HC Wainwright currently has a “Buy” …WebNasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ... Instagram:https://instagram. robots stocksnatural gas penny stockstop health insurance companies in nywhere i can buy shiba inu coin WESTLAKE VILLAGE, Calif. - Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the broad-market Russell 3000 Index and small-cap Russell 2000 at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. equity markets open on …Web how to read candle chartsfidelity multi asset income fund WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ... optionprofitcalculator Uncover the latest insider trading activity for Genelux Corporation (GNLX). Know which insiders are buying and selling along with top shareholders and ownership breakdown. Dashboard Markets Discover Watchlist Portfolios Screener. Genelux Corporation. NasdaqCM:GNLX Stock Report. Mkt Cap: US$317.1m. Add to watchlist.Genelux Corporation (NASDAQ:GNLX) fell 8.1% to $5.65. Genelux announced pricing of $15 million initial public offering of 2.5 million shares of common stock at a price of $6 per share.